Views & Analysis | Perspectives on pharma industry issues

Digital

Augmented intelligence: The next-gen engine for biopharma in...

Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.

Patients

Brain puzzle with piece missing, letting through the sunlight

Exploring mixed episodes in bipolar I disorder: When mania a...

One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.

R&D

Redefining drug discovery: Morocco’s biotech strategy for in...

Ongoing work in Morocco demonstrates how developing research infrastructure can support innovative approaches grounded in locally generated data.

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Digital

lady pointing at a number of data points

Solution Spotlight: Medscape AI

Medscape AI introduces a global, medical-grade AI search tool exclusively curated from the world’s largest body of clinically vetted content.

R&D

Net Treatment Benefit in rare disease trials: Aligning trial...

Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.

R&D

How innovative trial approaches are advancing rare disease r...

Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Sales & Marketing

Biotech is back, with Craig Ackerman

In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Sales & Marketing

Commercial teams are running yesterday's plays. AI just chan...

What leading companies are building now is fundamentally different: decision systems.

Digital

Augmented intelligence: The next-gen engine for biopharma in...

Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.

Digital

Solution Spotlight: Medscape AI

Medscape AI introduces a global, medical-grade AI search tool exclusively curated from the world’s largest body of clinically vetted content.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Market Access

A panel on direct-to-patient at Reuters Pharma USA

In DTC's watershed moment, trust and partnership are key

More and more pharma companies are turning to direct-to-patient access models. But the consensus at Reuters Pharma USA is that they can't do it alone.

Oncology

Interview with Vicky Brown at Pharma USA 2026

Hernexeos and what’s next, with Vicky Brown

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent US approval for Hernexeos in NSCLC.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

Oncology

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.